Search results for "Prostaglandin E"

showing 10 items of 98 documents

Immobilization and controlled release of prostaglandin E2 from poly-L-lactide-co-glycolide microspheres.

2009

Prostaglandin E(2) (PGE(2)) is an arachidonic acid metabolite involved in physiological homeostasis and numerous pathophysiological conditions. Furthermore, it has been demonstrated that prostaglandins have a stimulating effect not only on angiogenesis in situ and in vitro but also on chondrocyte proliferation in vitro. Thus, PGE(2) represents an interesting signaling molecule for various tissue engineering strategies. However, under physiological conditions, PGE(2) has a half-life time of only 10 min, which limits its use in biomedical applications. In the present study, we investigated if the incorporation of PGE(2) into biodegradable poly-L-lactide-co-glycolide microspheres results in a …

Materials scienceMetabolitemedicine.medical_treatmentKineticsBiomedical EngineeringProstaglandinDinoprostoneBiomaterialschemistry.chemical_compoundmedicineProstaglandin E2Particle SizePolyglactin 910ChromatographyMetals and AlloysControlled releaseIn vitroMicrospheresKineticschemistryBiochemistryDelayed-Action PreparationsCeramics and Compositeslipids (amino acids peptides and proteins)Arachidonic acidProstaglandin Emedicine.drugJournal of biomedical materials research. Part A
researchProduct

Cytokine-mediated regulation of monocyte/macrophage cytotoxicity in human immunodeficiency virus-1 infection.

1992

Monocyte/macrophage-mediated tumor cytotoxicity was studied in patients infected with human immunodeficiency virus-1 (HIV-1) at various stages [Center for disease control (CDC) classification] of the disease. using the P-815 tumor cell line as target cells, the results demonstrated reduced monocyte/macrophage cytotoxicity early in HIV-1-related disease (CDCIII, P0.01). This cellular dysfunction sustained during the progression of the disease. Evidence could be presented that neither exogenous application of macrophage-stimulating cytokines (e.g. interferons) nor their endogenous induction in vitro restored monocyte/macrophage cytotoxicity. However, enhanced tumor necrosis factor (TNF)-alpha…

Microbiology (medical)AdultCytotoxicity Immunologicmedicine.medical_treatmentImmunologyHIV InfectionsBiologyVirusMonocytesmedicineTumor Cells CulturedImmunology and AllergyMacrophageHumansProstaglandin E2CytotoxicityCells CulturedTumor Necrosis Factor-alphaMonocyteInterleukinsMacrophagesGeneral MedicineMiddle AgedIn vitroCytokinemedicine.anatomical_structureImmunologyHIV-1CytokinesTumor necrosis factor alphaInterferonsmedicine.drugMedical microbiology and immunology
researchProduct

LAAE-14, a new anti-inflammatory drug, increases the survival ofCandida albicans-inoculated mice

2003

LAAE-14, a lipidic acid-amido ether derivative, has been recently described as a new anti-inflammatory drug. We have studied the effect of treatment with this compound on the susceptibility of mice to in vivo experimental Candida albicans infection. ICR mice orally treated with LAAE-14 (25 mg kg(-1)) and experimentally intravenously infected showed a significantly increased survival as compared to control mice. In vitro, the compound did not inhibit the growth of C. albicans yeast cells or the yeast-to-hyphal transition. The in vitro production of prostaglandin E2 by peritoneal macrophages in response to the yeasts and hyphae of C. albicans was significantly decreased upon treatment with LA…

Microbiology (medical)Ratónmedicine.drug_classmedicine.medical_treatmentImmunologyHyphaeMicrobiologyDinoprostoneAnti-inflammatoryMicrobiologyGlutaratesMiceIn vivoCandida albicansmedicineAnimalsImmunology and AllergyProstaglandin E2Candida albicansCells CulturedMice Inbred ICRbiologyAnti-Inflammatory Agents Non-SteroidalCandidiasisGeneral Medicinebiology.organism_classificationSurvival AnalysisCorpus albicansIn vitroDisease Models AnimalInfectious DiseasesMacrophages PeritonealProstaglandin Emedicine.drugFEMS Immunology & Medical Microbiology
researchProduct

Dysidotronic acid, a new sesquiterpenoid, inhibits cytokine production and the expression of nitric oxide synthase.

2001

In a previous study, we reported a new bioactive sesquiterpenoid, named dysidotronic acid, to be a potent, selective human synovial phospholipase A(2) inhibitor. Dysidotronic acid is a novel, non-complex manoalide analogue lacking the pyranofuranone ring. We now investigate the effect of this compound on cytokine, nitric oxide and prostanoid generation on the mouse macrophage cell line RAW 264.7, where it showed a dose-dependent inhibition with inhibitory concentration 50% values in the micromolar range. This effect was also confirmed in the mouse air pouch injected with zymosan. Dysidotronic acid inhibited the production of tumor necrosis factor alpha and interleukin-1 beta as well as the …

Nitric oxide (NO)MouseLeukotriene B4NeutrophilsRAW 264.7Dysidotronic acidNitric Oxide Synthase Type IIDinoprostonePhospholipases ANitric oxideCell Linechemistry.chemical_compoundManoalideMicemedicineAnimalsHumansProstaglandin E2Enzyme InhibitorsCytokineNitritesPharmacologybiologyTumor Necrosis Factor-alphaMacrophagesZymosanZymosanMembrane ProteinsNitric oxide synthaseIsoenzymesAir pouchchemistryBiochemistryEnzyme inhibitorCyclooxygenase 2Prostaglandin-Endoperoxide Synthasesbiology.proteinCytokinesArachidonic acidDiterpenesNitric Oxide SynthaseSesquiterpenesmedicine.drugEuropean journal of pharmacology
researchProduct

Traditional Chinese herbal medicine at the forefront battle against COVID-19: Clinical experience and scientific basis.

2020

Abstract Background Throughout the 5000-year history of China, more than 300 epidemics were recorded. Traditional Chinese herbal medicine (TCM) has been used effectively to combat each of these epidemics’ infections, and saved many lives. To date, there are hundreds of herbal TCM formulae developed for the purpose of prevention and treatment during epidemic infections. When COVID-19 ravaged the Wuhan district in China in early January 2020, without a deep understanding about the nature of COVID-19, patients admitted to the TCM Hospital in Wuhan were immediately treated with TCM and reported later with >90% efficacy. Approach We conducted conduct a systematic survey of various TCM herbal pre…

PTGS2 Prostaglandin-endoperoxide synthase 2BattleAIV avian influenza virusCoV coronavirusPharmaceutical ScienceiNOS nitric oxide synthaseViral infection0302 clinical medicinePA patchouli alcoholSARS Severe Acute Respiratory SyndromeSMD Sheganmahuang decoctionDrug DiscoveryPandemicIL InterleukinMedicine Chinese TraditionalALI acute lung injuriesmedia_commonCOVID-19 coronavirus disease 2019MXSG Ma xing shi gan decoction0303 health sciencesTNF tumor necrosis factorClinical Trials as TopicCCL2 CC chemokine ligand 2FM1 FM1 coronavirusICU intensive care unitc-AMP cyclic adenosine phosphateHIV human immunodeficiency virus030220 oncology & carcinogenesisCOX-2 cyclooxygenase-2Molecular MedicineHerbal preparationsMedicinal herbsAbbreviations: ACE2 angiotensin-converting enzyme IITCM traditional Chinese medicineHSV-1 herpes simplex virus 1CASP3 caspase 3medicine.medical_specialtyChinaCoronavirus disease 2019 (COVID-19)Systematic surveymedia_common.quotation_subjectJEV Japanese encephalitis virusNF-κB nuclear factor kappa B cellsAntiviral AgentsArticleWHO World Health Organization03 medical and health sciencesIEC-6 rat intestinal epithelial cell line 6SOD superoxide dismutaseCDC Center for Disease Control and PreventionmedicineAVP arginine vasopressinPGE2 prostaglandin E2HumansIntensive care medicineLH Lianhuaqingwen capsule030304 developmental biologyPharmacologyMedicinal herbMDA malondialdehydeGCGJ Gancao ganjiang decoctionNO nitric oxidePlants Medicinalbusiness.industrySARS-CoV-2COVID-19CXCL C-X-C- motif chemokineMDCK Madin-Darby Canine Kidney cellsTLR-4 Toll-like receptor-4COVID-19 Drug TreatmentComplementary and alternative medicineViral infectionLPS lipopolysaccharidesRSV respiratory syncytial virusQFPD Qingfeipaidu decoctionbusinessLung congestionECMO extracorporeal membrane oxygenationMAPK mitogen-activated protein kinasePhytotherapyDrugs Chinese HerbalPhytomedicine : international journal of phytotherapy and phytopharmacology
researchProduct

Lung myofibroblasts are characterized by down-regulated cyclooxygenase-2 and its main metabolite, prostaglandin E2.

2013

Background: Prostaglandin E2 (PGE(2)), the main metabolite of cyclooxygenase (COX), is a well-known anti-fibrotic agent. Moreover, myofibroblasts expressing alpha-smooth muscle actin (alpha-SMA), fibroblast expansion and epithelial-mesenchymal transition (EMT) are critical to the pathogenesis of idiopathic pulmonary fibrosis (IPF). Our aim was to investigate the expression of COX-2 and PGE(2) in human lung myofibroblasts and establish whether fibroblast-myofibroblast transition (FMT) and EMT are associated with COX-2 and PGE(2) down-regulation. Methods: Fibroblasts obtained from IPF patients (n = 6) and patients undergoing spontaneous pneumothorax (control, n = 6) and alveolar epithelial ce…

PathologyPulmonologyMetaboliteImmunofluorescencelcsh:MedicineBiochemistrychemistry.chemical_compoundIdiopathic pulmonary fibrosisMolecular Cell BiologyPulmonary fibrosisProstaglandin E2Myofibroblastslcsh:ScienceLungCells CulturedFisiologia cel·lularMultidisciplinarybiologyFibrosi pulmonarrespiratory systemExtracellular Matrixmedicine.anatomical_structureCytokinesMedicinelipids (amino acids peptides and proteins)Immunohistochemical AnalysisMyofibroblastResearch ArticleSignal Transductionmedicine.drugmedicine.medical_specialtyEpithelial-Mesenchymal TransitionImmunologyInterstitial Lung DiseasesDinoprostonePulmonary fibrosisTransforming Growth Factor beta1ImmunofluorescènciaGrowth FactorsCell Line TumormedicineHumansEpithelial–mesenchymal transitionFibroblastBiologyCell Proliferationlcsh:RProteinsEpithelial Cellsmedicine.diseaseActinsIdiopathic Pulmonary Fibrosisrespiratory tract diseasesGene Expression RegulationchemistryCyclooxygenase 2Immune SystemCase-Control StudiesImmunologic Techniquesbiology.proteinCancer researchClinical Immunologylcsh:QCyclooxygenaseBiomarkersPLoS ONE
researchProduct

Microvascular in vivo assessment of reperfusion injury: significance of prostaglandin E1 and I2 in postischemic “no-reflow” and “reflow-paradox”

2004

Microvascular ischemia-reperfusion (I/R) injury is characterized by failure of capillary perfusion ("no-reflow") and reoxygenation-associated phenomena ("reflow-paradox"), including activation of leukocyte-endothelium interaction with cytotoxic mediator-induced loss of endothelial integrity. The objectives of this study were to elucidate the impact of both prostaglandins E(1) (PGE(1)) and I(2) (PGI(2)) in microvascular reperfusion injury, with special focus on the distinct pathophysiology of no-reflow- and reflow-paradox phenomena.By use of the hamster dorsal skinfold preparation and in vivo fluorescence microscopy, the microcirculation of a striated skin muscle was assessed before 4 h of p…

Pathologymedicine.medical_specialtyEndotheliummedicine.medical_treatmentIschemiaPharmacologyMicrocirculationCapillary Permeabilitychemistry.chemical_compoundIn vivoCricetinaemedicineAnimalsVascular Diseasescardiovascular diseasesAlprostadilMuscle SkeletalProstaglandin E1SkinMicroscopyMesocricetusbusiness.industryMicrocirculationmedicine.diseaseEpoprostenolPathophysiologyCapillariesChemotaxis Leukocytemedicine.anatomical_structurechemistryReperfusion InjuryModels Animalcardiovascular systemSurgeryEndothelium VascularbusinessReperfusion injuryPlatelet Aggregation InhibitorsProstaglandin EJournal of Surgical Research
researchProduct

Changes in crevicular cytokines after application of melatonin in patients with periodontal disease

2017

Background A clinical trial was designed to evaluate the effects of topical application of melatonin on the crevicular fluid levels of interleukins and prostaglandins and to evaluate changes in clinical parameters. Material and methods A consecutive sample of 90 patients were recruited from the Health Centre of Pinos Puente in Granada, Spain and divided into 3 groups: 30 patients with diabetes and periodontal disease, who were given melatonin; 30 patients with diabetes and periodontal disease, who were given a placebo, and 30 healthy individuals with no history of systemic disease or clinical signs of periodontal disease, who were also given a placebo. The 30 patients with diabetes and peri…

Periodontitismedicine.medical_specialtySystemic diseasebusiness.industryResearchInterleukin030206 dentistrymedicine.diseasePlacebo:CIENCIAS MÉDICAS [UNESCO]GastroenterologyMelatoninClinical trial03 medical and health sciences0302 clinical medicineDiabetes mellitusInternal medicineUNESCO::CIENCIAS MÉDICASmedicinePeriodontologyProstaglandin E2businessGeneral Dentistry030217 neurology & neurosurgerymedicine.drug
researchProduct

Prostanoid receptors of the EP3 subtype mediate inhibition of evoked [3 H]acetylcholine release from isolated human bronchi

1998

1 The release of neuronal [3H]acetylcholine (ACh) from isolated human bronchi after labelling with [3H]choline was measured to investigate the effects of prostanoids. 2 A first period of electrical field stimulation (S1) caused a [3H]ACh release of 320±70 and 200±40 Becquerel (Bq) g−1 in epithelium-denuded and epithelium-containing bronchi respectively (P>0.05). Subsequent periods of electrical stimulation (Sn, n=2, 3, and 4) released less [3H]ACh, i.e. decreasing Sn/S1 values were obtained (0.76±0.09, 0.68±0.07 and 0.40±0.04, respectively). 3 Cumulative concentrations (1–1000 nM) of EP-receptor agonists like prostaglandin E2, nocloprost, and sulprostone (EP1 and EP3 selective) inhibited ev…

PharmacologyAgonistmedicine.medical_specialtybiologyChemistrymedicine.drug_classProstanoidStimulationchemistry.chemical_compoundEndocrinologyInternal medicinebiology.proteinmedicinelipids (amino acids peptides and proteins)CyclooxygenaseProstaglandin E2ReceptorNeurotransmitterAcetylcholinemedicine.drugBritish Journal of Pharmacology
researchProduct

Modulation of haem oxygenase-1 expression by nitric oxide and leukotrienes in zymosan-activated macrophages

2001

Phagocytosis of unopsonized zymosan by RAW 264.7 macrophages upregulated protein expression of haem oxygenase-1 (HO-1), inducible nitric oxide synthase (iNOS) and cyclo-oxygenase-2 (COX-2) in a time- and concentration-dependent manner. In the presence of zymosan, exogenous prostaglandin E(2) (PGE(2)) did not exert significant effects on the expression of these three enzymes. In contrast, exogenous leukotriene B(4) (LTB(4)) and LTC(4) in the nanomolar range inhibited HO-1 and iNOS expression, as well as nitrite accumulation. The COX inhibitors indomethacin and NS398 weakly inhibited HO-1 expression but had no effect on iNOS and COX-2 expression or nitrite. In contrast, the 5-lipoxygenase (5-…

PharmacologyCellular immunitybiologyLeukotriene B4medicine.medical_treatmentZymosanZileutonMolecular biologyNitric oxideNitric oxide synthasechemistry.chemical_compoundchemistryBiochemistryArachidonate 5-lipoxygenasebiology.proteinmedicineProstaglandin Emedicine.drugBritish Journal of Pharmacology
researchProduct